Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?

Link to article at PubMed

Med Mycol Case Rep. 2021 Mar;31:32-34. doi: 10.1016/j.mmcr.2021.01.002. Epub 2021 Jan 21.


Tocilizumab is widely being used to treat COVID-19. Although reducing systemic inflammation, it also increases the risk for secondary infections as a result of the immunosuppression produced. We report the case of a 69-year-old patient admitted to the ICU with severe respiratory distress caused by COVID-19 pneumonia who developed pulmonary aspergillosis. On the basis of these findings, we suggest early testing for pulmonary aspergillosis in COVID-19 patients treated with tocilizumab.

PMID:33520634 | PMC:PMC7826035 | DOI:10.1016/j.mmcr.2021.01.002

Leave a Reply

Your email address will not be published.